The prevalence of diffuse large B-cell lymphoma (DLBCL) is increasing across the world due in part to the increased technological advances in the treatment of DLBCL.
Investigative efforts to define patient subsets associated with favorable or unfavorable prognosis focus on clinical factors recognized in the International Prognostic Index (IPI), gene expression profiles such as germinal center B-cell (GCB) or activated B-cell (ABC) gene expression, and molecular factors such as characterized by immunohistochemistry.
Understanding the biological heterogeneity of DLBCL leads to a more patient-specific and genetically based approach toward the treatment of this disease
Approximately 10% to 15% of patients who receive R-CHOP will have an incomplete response or relapse within 6 months, and an additional 20% to 25% will relapse after an initial response, or within the first 2 years. “Outcomes remain poor for patients in whom frontline treatment fails,” reviewers said.
For patients with chemotherapy-sensitive relapsed or refractory disease, high-dose chemotherapy with autologous stem-cell transplantation “offers the best chance of cure.” Most relapsed or refractory patients, however, are transplant-ineligible, and palliative treatment has involved rituximab, gemcitabine, and oxaliplatin. Chimeric antigen receptor (CAR) T-cell therapy has been a recent option with the potential for durable disease remission.
Antibody-drug conjugates, which selectively deliver tumor-toxic payloads, have shown promise, such as polatuzumab vedotin, which in combination with bendamustine-rituximab has received regulatory approval. Many novel individual and combination therapies are currently being studied in clinical trials for the treatment of patients with both newly diagnosed and relapsed/refractory DLBCL.
Wondering how to make the most of the fast growth the DLBCL therapeutics industry is experiencing?
Our syndicated study captures real-world data from real-world patient chart information to provide a holistic analysis of the development of this evolving market.
This tracker collects information from over 375 European hematologists/oncologists, each of whom provides data on their medical practice as well as current and historical information from 5 to 7 randomly selected R/R DLBCL patient charts.
The insights detailed in the study report allow marketing, market insights, and market research teams to gain an in-depth understanding of the DLBCL treatment market.
We have back-data from the US, UK, FR, DE, IT, ES, and a new wave is launching in 2023 in the UK, DE, FR, IT, ES, AU, CA, BE, CH, NL, PL, and IL.
Products covered include CAR-T
CAR T-cell therapy is a promising treatment for refractory patients with aggressive non-Hodgkin lymphoma (NHL). It is a highly specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved three CAR T-cell therapies for lymphoma: Yescarta™ (KITE / Gilead), and Kymriah™ (Novartis), and more recently in early 2021 Bristol Myers’ Breyanzi.
- YESCARTA (axicabtagene ciloleucel) is currently approved for aggressive, R/R DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. In clinical trials, Yescarta was shown to be highly effective with 82 % of patients responding to the therapy, including 54% with complete response (CR). The most recent follow-up data shows that at a median 15.4 months after treatment, 40 percent of patients remain in complete remission, showing the lasting effectiveness of this therapy.
The phase 3 Zuma-7 trial, pitting Yescarta as a second-line treatment for DLBCL against standard of care. That study was launched about a year ahead of Breyanzi’s Transform trial but enrolled nearly twice as many patients.
June 2021: Top-line results from the primary analysis of ZUMA-7, a randomized Phase 3 global, multicenter study showing superiority of Yescarta compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL). Yescarta® improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
- KYMRIAH (tisagenlecleucel) is also in R/R large B-cell lymphoma including DLBCL, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma, as well as R/R B-cell acute lymphoblastic leukemia (ALL) up to age 25.
- BREYANZI (lisocabtagene maraleucel) is also used to to treat LBCL patients after two or more lines of systemic therapy. With the latest result, BMS said it’s going to share the data from the phase 3 Transform trial with regulators in hopes of moving up one line in the treatment sequence.
Extract from the DLBCL Study Overview (available on request)
This study deep dives on the following areas:
DLBCL Market Background
- Change in product usage
- Expected future prescribing
- Evolving brand awareness
- Differences by country
DLBCL Brand Performance
- Brand penetration and shares by line
- Choice attributes by line of therapy
- Retreatment by regimen and line of therapy
- Share evolution and the impact of new product launches
- Differences in each EU5 country
DLBCL Patient Insights
- DLBCL patient profile by regimen (e.g., chemotherapy, CAR T-cells, and other branded agents)
- DLBCL patient profile by line
- Line by line break-out of SCT-eligible vs. SCT-ineligible patients
- Relapse times by regimen
- Diagnosis and referral process
- Detailed treatment pattern
- Planned treatment durations
- Patient request/role in decision process
Go further with the data and discover an example of a Digital & Interactive Dashboard (DID) created by APLUSA
We take here the example of a patient share tracker in Cancer X syndiTrackTM.
The dashboard is built around 6 variables: the country, the treatment start date, the treatment line, the product or regimen, risk factors and market share.
In total, there are many advantages of using this DID:
- your data is available online and can be easily shared within your organization,
- you can create your own views instead of manipulating a large number of powerpoint slides,
- you always have the latest data available, no update problems,
- the data is available on your dashboard much earlier in the data collection,
- the report will be more focused on key insights and storytelling than on data production.
👇 Test our live demo here! 👇